Cargando…

Intracranial efficacy and safety of furmonertinib 160 mg with or without anti-angiogenic agent in advanced NSCLC patients with BM/LM as salvage therapy

OBJECTIVES: Central nervous system (CNS) metastases including brain metastases (BM) and leptomeningeal metastases (LM) are frequent in epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC), and are correlated with poor outcomes. In this study, we evaluated the efficacy o...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xu, Ziyi, Hao, Xuezhi, Wang, Qi, Yang, Ke, Li, Junling, Xing, Puyuan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9985196/ https://www.ncbi.nlm.nih.gov/pubmed/36870951 http://dx.doi.org/10.1186/s12885-023-10676-x

Ejemplares similares

Bevacizumab Combined with Continuation of EGFR-TKIs in NSCLC Beyond Gradual Progression
por: Xu, Ziyi, et al.
Publicado: (2022)

Efficacy and safety profile of combining programmed cell death‐1 (PD‐1) inhibitors and antiangiogenic targeting agents as subsequent therapy for advanced or metastatic non‐small cell lung cancer (NSCLC)
por: Xu, Ziyi, et al.
Publicado: (2021)

Intracranial efficacy of alectinib in ALK-positive NSCLC patients with CNS metastases—a multicenter retrospective study
por: Zou, Zihua, et al.
Publicado: (2022)

Concurrent chemotherapy and first‐generation epidermal growth factor receptor (EGFR)‐tyrosine kinase inhibitors (TKIs) with or without an antiangiogenic agent as first‐line treatment in advanced lung adenocarcinoma harboring an EGFR mutation
por: Xu, Ziyi, et al.
Publicado: (2021)

The role of weekly nanoparticle albumin bound paclitaxel monotherapy as second line or later treatment for advanced NSCLC in China
por: Xing, Puyuan, et al.
Publicado: (2017)

Successful salvage therapy using high-dose furmonertinib (AST2818) for non–small-cell lung cancer after Osimertinib resistance: a case report
por: Cheng, Daoan, et al.
Publicado: (2022)

Clinical Modality of Resistance and Subsequent Management of Patients with Advanced Non-small Cell Lung Cancer Failing Treatment with Osimertinib
por: Mu, Yuxin, et al.
Publicado: (2019)

Study protocol: A single‐arm, multicenter, phase II trial of camrelizumab plus apatinib for advanced nonsquamous NSCLC previously treated with first‐line immunotherapy
por: Xing, Puyuan, et al.
Publicado: (2021)

Determination of Osimertinib, Aumolertinib, and Furmonertinib in Human Plasma for Therapeutic Drug Monitoring by UPLC-MS/MS
por: Li, Ying, et al.
Publicado: (2022)

Efficacy of Osimertinib After Progression of First-Generation Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor (EGFR-TKI) in EGFR-Mutated Lung Adenocarcinoma: A Real-World Study in Chinese Patients
por: Xu, Ziyi, et al.
Publicado: (2022)

Immune checkpoint inhibitor rechallenge in advanced or metastatic non-small cell lung cancer: a retrospective cohort study
por: Xu, Ziyi, et al.
Publicado: (2022)

Efficacy and safety of brigatinib in ALK-positive non-small cell lung cancer treatment: A systematic review and meta-analysis
por: Xing, Puyuan, et al.
Publicado: (2022)

Evolutionary Characteristics and Immunologic Divergence of Lung and Brain Metastasis Lesions in NSCLC
por: Xie, Tongji, et al.
Publicado: (2023)

First-line immunotherapy or angiogenesis inhibitor plus chemotherapy for HER2-altered NSCLC: a retrospective real-world POLISH study
por: Yang, Guangjian, et al.
Publicado: (2022)

Factors involved in the anti-cancer activity of the investigational agents LM985 (flavone acetic acid ester) and LM975 (flavone acetic acid).
por: Bibby, M. C., et al.
Publicado: (1987)

A multicenter, randomized, and double-blind phase IV clinical trial to compare the efficacy and safety of fixed-dose combinations of amlodipine orotate/valsartan 5/160 mg versus valsartan/hydrochlorothiazide 160/12.5 mg in patients with essential hypertension uncontrolled by valsartan 160 mg monotherapy
por: Ahn, Youngkeun, et al.
Publicado: (2018)

Expression of murine Lm-1 locus. Lm-1 determinants on lymphocytes and macrophages, and effects of Lm-1 incompatibility on bone marrow grafts
Publicado: (1985)

EGFR amplification is a putative resistance mechanism for NSCLC–LM patients with TKI therapy and is associated with poor outcome
por: Yang, Hainan, et al.
Publicado: (2022)

Advanced pancreatic cancer with KRAS wild-type and EGFR-sensitive mutation respond favorably to furmonertinib: A case report
por: Ma, Xiaoting, et al.
Publicado: (2023)

Acquired resistance to osimertinib in patients with non-small-cell lung cancer: mechanisms and clinical outcomes
por: Mu, Yuxin, et al.
Publicado: (2020)

Afatinib treatment response in advanced lung adenocarcinomas harboring uncommon mutations
por: Li, Teng, et al.
Publicado: (2021)

BmCDK5 Affects Cell Proliferation and Cytoskeleton Morphology by Interacting with BmCNN in Bombyx mori
por: Wei, Yi, et al.
Publicado: (2022)

Pharmacokinetic Study of a Novel Antihyperlipidemic Agent LM-13765- A Prodrug
por: Shah, T. M., et al.
Publicado: (2009)

Efficacy and safety of afatinib in a Chinese population with advanced lung adenocarcinoma with sensitive EGFR mutations
por: Wang, Shouzheng, et al.
Publicado: (2019)

Clinical effect of pemetrexed as the first‐line treatment in Chinese patients with advanced anaplastic lymphoma kinase‐positive non‐small cell lung cancer
por: Ma, Di, et al.
Publicado: (2016)

Clinical data from the real world: efficacy of Crizotinib in Chinese patients with advanced ALK-rearranged non-small cell lung cancer and brain metastases
por: Xing, Puyuan, et al.
Publicado: (2016)

Real-World Data Of Osimertinib In Patients With Pretreated Non-Small Cell Lung Cancer: A Retrospective Study
por: Mu, Yuxin, et al.
Publicado: (2019)

Valsartan 160 mg/Amlodipine 5 mg Combination Therapy versus Amlodipine 10 mg in Hypertensive Patients with Inadequate Response to Amlodipine 5 mg Monotherapy
por: Sung, Jidong, et al.
Publicado: (2016)

Epithelial circulating tumor cells with a heterogeneous phenotype are associated with metastasis in NSCLC
por: Zhang, Yujuan, et al.
Publicado: (2021)

Efficacy of dacomitinib in patients with EGFR‐mutated NSCLC and brain metastases
por: Zhang, Jinyao, et al.
Publicado: (2021)

Persistent response of furmonertinib plus anlotinib in a lung adenocarcinoma patient with an EGFR exon 20 insertion mutation: A case report
por: Chen, Xuesong, et al.
Publicado: (2023)

Quadrupoles type IX and X: Drawings 202-010 LM 1 and 202-013 LM 1
por: Boltezar, E
Publicado: (1974)

Heterogeneity in intracranial relapses after complete resection of lung adenocarcinoma: Distinct features of brain‐only relapse versus synchronous extracranial relapse
por: Xu, Fei, et al.
Publicado: (2023)

Clinical outcome, long‐term survival and tolerability of sequential therapy of first‐line crizotinib followed by alectinib in advanced ALK+NSCLC: A multicenter retrospective analysis in China
por: Zou, Zihua, et al.
Publicado: (2021)

Survival Outcomes of Salvage Therapy for Local and Regionally Recurrent NSCLC
por: Moore, Sara, et al.
Publicado: (2020)

Nab-paclitaxel in combination with Bevacizumab in patients with non-squamous non-small cell lung cancer after failure of at least one prior systemic regimen
por: Hao, Xuezhi, et al.
Publicado: (2020)

Turbinas de gas LM2500/
por: Aguilar Domínguez, Hugo
Publicado: (2005)

The contribution of LM to the neuroscience of movement vision
por: Zihl, Josef, et al.
Publicado: (2015)

ultraLM and miniLM: Locator tools for smart tracking of fluorescent cells in correlative light and electron microscopy
por: Brama, Elisabeth, et al.
Publicado: (2016)

Successful therapy using high-dose furmonertinib for non-small cell lung cancer with leptomeningeal metastasis: a case report and literature review
por: Chen, Ting, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_rerl6llba80b7rpad0f87bsp45